AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Placebo + SoC chemotherapy
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 89
- Registration Number
- NCT04385368
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
Phase 4
Terminated
- Conditions
- Unresectable Stage III NSCLC
- Interventions
- Device: Multiparametric Mobile Technology
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04381494
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT04380688
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 413
- Registration Number
- NCT04379596
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT04365218
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Other: Placebo
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT04362410
- Locations
- 🇨🇳
Research Site, Nanchang, China
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Phase 3
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 358
- Registration Number
- NCT04351555
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 177
- Registration Number
- NCT04346199
- Locations
- 🇹🇷
Research Site, Umraniye, Turkey
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 202
- Registration Number
- NCT04330040
- Locations
- 🇮🇳
Research Site, Vellore, India
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
Phase 2
Completed
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 159
- Registration Number
- NCT04327024
- Locations
- 🇸🇰
Research Site, Svidnik, Slovakia
© Copyright 2025. All Rights Reserved by MedPath